- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07691762
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
A Phase III, Randomized, Double-blind, Multicenter Study of SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Junqin Yang
- Telefonnummer: +86-0518-82342973
- E-mail: junqin.yang@hengrui.com
Undersøgelse Kontakt Backup
- Navn: Huan Wang
- Telefonnummer: +86-0518-82342973
- E-mail: huan.wang.hw396@hengrui.com
Studiesteder
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210009
- Zhongda Hospital Southeast University
-
Ledende efterforsker:
- Gaojun Teng
-
Kontakt:
- Gaojun Teng
- Telefonnummer: +86-025-83272084
- E-mail: gjteng@seu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Zhongshan Hospital, Fudan University
-
Ledende efterforsker:
- Jia Fan
-
Kontakt:
- Jia Fan
- Telefonnummer: +86-021-64041990
- E-mail: fan.jia@zs-hospital.sh.cn
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18-75 years old, male or female;
- Diagnosis confirmed HCC by pathologically or clinically;
- At least one measurable lesion;
- Child-Pugh liver function grade A;
- ECOG-PS score: 0 or 1;
- Eligible for TACE treatment as assessed by the investigator;
- Participants with HBV or HCV infection must be on and remain on standard antiviral therapy throughout the study period;
- Consent to contraception.
Exclusion Criteria:
- Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years;
- Participants with any active, known or suspected autoimmune disorder;
- Participants with hypertension which cannot be well controlled by antihypertensives;
- Uncontrolled cardiac diseases or symptoms;
- Participants with hepatic encephalopathy;
- Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment;
- History of gastrointestinal perforation and/or fistula;
- Participants with other potential factors that may affect the study results.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Treatment group A
SHR-8068 + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE) |
SHR-8068 + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE) |
|
Aktiv komparator: Treatment group B
SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo + Transarterial Chemoembolization (TACE) |
SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, intravenous infusion, Transarterial Chemoembolization(TACE) |
|
Eksperimentel: Treatment group C
SHR-8068 Placebo + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE) |
SHR-8068 Placebo + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Progression-free survival (PFS) assessed by investigator
Tidsramme: Until progression, assessed up to approximately 2 years.
|
Until progression, assessed up to approximately 2 years.
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Adverse events (AEs)
Tidsramme: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Serious adverse events (SAEs)
Tidsramme: Until study completion, assessed up to approximately 3 years.
|
Until study completion, assessed up to approximately 3 years.
|
|
Progression-free survival (PFS) assessed by Blinded Independent Review Committee (BIRC)
Tidsramme: Until progression, assessed up to approximately 2 years.
|
Until progression, assessed up to approximately 2 years.
|
|
Overall survival (OS)
Tidsramme: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Objective response rate (ORR)
Tidsramme: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Disease control rate (DCR)
Tidsramme: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Duration of objective tumor response (DoR)
Tidsramme: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Pharmacokinetics parameters of SHR-8068 and Adebrelimab: serum concentration
Tidsramme: Approximately 90 days post-last dose.
|
Approximately 90 days post-last dose.
|
|
Immunogenicity indicators of SHR-8068 and Adebrelimab: drug resistant antibody (ADA) and neutralizing antibody (NAb)
Tidsramme: Approximately 90 days post-last dose.
|
Approximately 90 days post-last dose.
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Leversygdomme
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplasmer i leveren
- Karcinom
- Carcinom, hepatocellulært
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Bevacizumab
Andre undersøgelses-id-numre
- SHR-8068-305
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .